Week In Review: Three China In-Licensing Deals Add Up To $662 Million

COVID-19 Pandemic 

  • Jiangxi Jemincare Group was approved to start US clinical trials of its SARS-CoV-2 neutralizing antibody, JMB2002, which was developed by the Jemincare Shanghai Research Center (see story). The company published data in February showing that, in preclinical studies, JMB2002 displayed strong prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus macaques. In January, Jemincare started a China Phase I clinical trial of the candidate in healthy volunteers. The company is headquartered in Nanchang. 
  • Beijing's Sinovac (SVA) reported that it now has the ability to manufacture two billion doses annually of CoronaVac®, its inactivated COVID-19 vaccine (see story). So far, the company has delivered 200 million doses of the vaccine to over 20 countries, including China. Sinovac believes that over 100 million doses of CoronaVac have been administered during the rollout. In 2020, Sino Biopharma (SBMFF) invested $515 million in a Sinovac subsidiary to double production of the inactivated vaccine.  

Trials and Approvals 

View single page >> |

Disclosure: None

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.